摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-{9-[(2R,4S,5R)-5-Azidomethyl-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide | 184229-77-4

中文名称
——
中文别名
——
英文名称
N-{9-[(2R,4S,5R)-5-Azidomethyl-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide
英文别名
——
N-{9-[(2R,4S,5R)-5-Azidomethyl-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide化学式
CAS
184229-77-4
化学式
C33H34N8O3Si
mdl
——
分子量
618.77
InChiKey
PUQOJYUOMGLEOS-UPRLRBBYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.62
  • 重原子数:
    45.0
  • 可旋转键数:
    9.0
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    139.92
  • 氢给体数:
    1.0
  • 氢受体数:
    8.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-{9-[(2R,4S,5R)-5-Azidomethyl-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide 在 palladium on activated charcoal 吡啶四丁基氟化铵氢气N,N-二异丙基乙胺 作用下, 以 四氢呋喃乙醇二氯甲烷 为溶剂, 25.0 ℃ 、101.33 kPa 条件下, 反应 15.0h, 生成
    参考文献:
    名称:
    Alteration of DNA Primary Structure by DNA Topoisomerase I. Isolation of the Covalent Topoisomerase I−DNA Binary Complex in Enzymatically Competent Form
    摘要:
    DNA ligation by DNA topoisomerase I was investigated employing synthetic DNA substrates containing a single strand nick. Site-specific cleavage of the DNA by topoisomerase I in proximity to the nick resulted in uncoupling of the cleavage and ligation reactions of the enzyme, thereby trapping the covalent enzyme-DNA intermediate. DNA cleavage could be reversed by the addition of acceptor oligonucleotides containing a free 5'-OH group and capable of hybridizing to the noncleaved strand of the ''suicide substrates''. Utilizing accepters with partial complementarity, modification of nucleic acid structure has been obtained. Modifications included the formation of DNA insertions, deletions, and mismatches. To further evaluate the potential of topoisomerase I to mediate structural transformations of DNA, acceptor oligonucleotides containing nucleophiles other than OH groups at the 5'-end were studied as substrates for the topoisomerase I-mediated ligation reaction. Toward this end, oligonucleotides containing 5'-thio, amino, and hydroxymethylene moieties were synthesized. Initial investigations utilizing a coupled cleavage-ligation assay suggested that only the modified acceptor containing an additional methylene group underwent efficient enzyme-mediated ligation. However, as linear DNA is not a preferred substrate for topoisomerase I, the enzyme-DNA intermediate was purified to homogeneity, thereby allowing investigation of the ligation reaction independent of the forward reaction that formed the covalent binary complex. The isolated complex consisted of equimolar enzyme and DNA, with topoisomerase I covalently bound to a specific site on the DNA duplex in an enzymatically competent form. Displacement of the enzyme-linked tyrosine moiety of the enzyme-DNA binary complex was effected by all the modified acceptor oligonucleotides, affording unnatural internucleosidic linkages at a specific site. Characterization of the formed linkages was effected both by enzymatic and chemical degradation studies. Comparative analysis revealed overall differences in the efficiency and rate of the topoisomerase I-mediated ligation of the modified acceptors. Moreover, the facility of ligation of the amino acceptor was significantly enhanced at increasing pH values. In addition, the method utilized to obtain the topoisomerase I-DNA intermediate is capable of affording large quantities required for further mechanistic and physicochemical characterization of the formed binary complex.
    DOI:
    10.1021/ja961788h
  • 作为产物:
    描述:
    Toluene-4-sulfonic acid (2R,3S,5R)-5-(6-benzoylamino-purin-9-yl)-3-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-ylmethyl ester 在 sodium azide 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.25h, 以95%的产率得到N-{9-[(2R,4S,5R)-5-Azidomethyl-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide
    参考文献:
    名称:
    Alteration of DNA Primary Structure by DNA Topoisomerase I. Isolation of the Covalent Topoisomerase I−DNA Binary Complex in Enzymatically Competent Form
    摘要:
    DNA ligation by DNA topoisomerase I was investigated employing synthetic DNA substrates containing a single strand nick. Site-specific cleavage of the DNA by topoisomerase I in proximity to the nick resulted in uncoupling of the cleavage and ligation reactions of the enzyme, thereby trapping the covalent enzyme-DNA intermediate. DNA cleavage could be reversed by the addition of acceptor oligonucleotides containing a free 5'-OH group and capable of hybridizing to the noncleaved strand of the ''suicide substrates''. Utilizing accepters with partial complementarity, modification of nucleic acid structure has been obtained. Modifications included the formation of DNA insertions, deletions, and mismatches. To further evaluate the potential of topoisomerase I to mediate structural transformations of DNA, acceptor oligonucleotides containing nucleophiles other than OH groups at the 5'-end were studied as substrates for the topoisomerase I-mediated ligation reaction. Toward this end, oligonucleotides containing 5'-thio, amino, and hydroxymethylene moieties were synthesized. Initial investigations utilizing a coupled cleavage-ligation assay suggested that only the modified acceptor containing an additional methylene group underwent efficient enzyme-mediated ligation. However, as linear DNA is not a preferred substrate for topoisomerase I, the enzyme-DNA intermediate was purified to homogeneity, thereby allowing investigation of the ligation reaction independent of the forward reaction that formed the covalent binary complex. The isolated complex consisted of equimolar enzyme and DNA, with topoisomerase I covalently bound to a specific site on the DNA duplex in an enzymatically competent form. Displacement of the enzyme-linked tyrosine moiety of the enzyme-DNA binary complex was effected by all the modified acceptor oligonucleotides, affording unnatural internucleosidic linkages at a specific site. Characterization of the formed linkages was effected both by enzymatic and chemical degradation studies. Comparative analysis revealed overall differences in the efficiency and rate of the topoisomerase I-mediated ligation of the modified acceptors. Moreover, the facility of ligation of the amino acceptor was significantly enhanced at increasing pH values. In addition, the method utilized to obtain the topoisomerase I-DNA intermediate is capable of affording large quantities required for further mechanistic and physicochemical characterization of the formed binary complex.
    DOI:
    10.1021/ja961788h
点击查看最新优质反应信息

同类化合物

鲁西他滨 化合物 T14195 [1,1'-联苯基]-2,3,3',4,4',5'-六醇 [(2R,3R,5S)-3-(氨基甲基)-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]N-[[(2R,3S,5R)-3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]氨基甲酸酯 9-(2-S-苯甲基-5-脱氧-2-硫代五呋喃糖基)-9H-嘌呤-6-胺 5-脱氧胸苷 5-脱氧-5-[(碘乙酰基)氨基]-胸腺嘧啶脱氧核苷 5-碘-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-5-脱氧胸腺嘧啶脱氧核苷 5-氨基-2,5-二脱氧腺苷酸 5-叠氮基-5-脱氧胸腺嘧啶脱氧核苷 5-三氟乙酰氨基-5-脱氧胸腺嘧啶脱氧核苷 5'-脱氧-5'氟胸苷 5'-脱氧-5'-氯胸苷-3'-(4-硝基苯基)硫代磷酸酯 5'-脱氧-5'-{[4-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-{[3-(甲硫基)苯胺基羰基]氨基}胸苷 5'-脱氧-5'-[4-苯基-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(甲硫基)苯甲酰氨基]胸苷 5'-脱氧-5'-[4-(吡啶-3-基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-[4-(4-氟苯基)-(1,2,3)三唑-1-基]胸苷 5'-脱氧-5'-<(苯氧基羰基)氨基>胸苷 5'-硫代-胸苷3',5'-二乙酸酯 5'-溴乙酰氨基-5'-脱氧胸苷 5'-氨基-5-碘-2',5'-二脱氧尿苷 4-氨基-1-((2R,3R,4R,5R)-4-((叔丁基二甲基硅烷基)氧基)-5-(( 2-氯-N-[[3-羟基-5-(5-甲基-2,4-二氧代嘧啶-1-基)四氢呋喃-2-基]甲基]乙酰胺 2-{[(2Z)-3,7-二甲基辛-2,6-二烯-1-基](亚硝基)氨基}乙醇 2,5-二脱氧腺苷 2',5'-二脱氧尿苷 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]嘧啶-2,4-二酮 1-[(2R,4S,5R)-4-羟基-5-(异氰基甲基)四氢呋喃-2-基]-5-甲基嘧啶-2,4-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)嘧啶-2,4(1H,3H)-二酮 1-(2,5-二脱氧-2-氟-β-D-呋喃阿拉伯糖基)-5-碘嘧啶-2,4(1H,3H)-二酮 N-{9-[(2R,4S,5R)-5-Azidomethyl-4-(tert-butyl-diphenyl-silanyloxy)-tetrahydro-furan-2-yl]-9H-purin-6-yl}-benzamide (Z)-4-(1-(((2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3-((1-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl)-1H-1,2,3-triazol-4-ylamino)-4-oxobutane-1,2-diyl dioleate 5'-[4-((1,2-distearoyl-sn-glycer-1-yl)methyl)-1H-1,2,3-triazol-1-yl]-N-3-propargylthymidine 5'-deoxy-5'-hydrazinothymidine hydrochloride N-<5'-Desoxy-thymidinyl-(5')>-phosphorsaeure-<β,β,β-trichlorethylester>-amid Acetic acid (2S,3S,5R)-2-fluoromethyl-5-(5-methyl-2-oxo-4-thioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl ester N-<5'-Desoxy-thymidinyl-(5')>-phosphorsaeure--amid N-<5'-Desoxy-thymidinyl-(5')>-phosphorsaeure-bis--amid N4-Benzoyl-5'-chlor-2',5'-dideoxycytidin 5'-(bromoacetamido)-2',5'-dideoxy-5-iodouridine 5'-[3-(3-methoxy-2-methyl-acryloyl)-ureido]-5'-deoxy-thymidine 3'-deoxy-5'- O-methyl-3'-(N-(L-p-methoxyphenylalanyl)amino)adenosine 1-(2-deoxy-2-fluoro-4-C-methyl-β-D-arabinofuranosyl)cytosine hydrochloride 5'-N-Isobutyloxycarbonyl-5'-amino-5'-deoxythymidin 4'-chloromethyl-2'-deoxy-2'-fluoro-3'-O-dodecanoylcytidine 3'-O-methylene-5'-deoxy-5'-thiothymidylyl-(3'->5')-N6-benzoyl-3'-O-tert-butyldimethylsilyl-2',5'-dideoxy-5'-thioadenosine